Logo image of INNV

INNOVAGE HOLDING CORP (INNV) Stock Fundamental Analysis

NASDAQ:INNV - Nasdaq - US45784A1043 - Common Stock - Currency: USD

2.89  -0.26 (-8.25%)

Premarket: 2.4 -0.49 (-16.96%)

Fundamental Rating

2

Taking everything into account, INNV scores 2 out of 10 in our fundamental rating. INNV was compared to 102 industry peers in the Health Care Providers & Services industry. INNV has a bad profitability rating. Also its financial health evaluation is rather negative. INNV is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year INNV has reported negative net income.
In the past year INNV had a positive cash flow from operations.
In the past 5 years INNV reported 4 times negative net income.
In multiple years INNV reported negative operating cash flow during the last 5 years.
INNV Yearly Net Income VS EBIT VS OCF VS FCFINNV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

1.2 Ratios

INNV's Return On Assets of -4.90% is on the low side compared to the rest of the industry. INNV is outperformed by 70.59% of its industry peers.
The Return On Equity of INNV (-10.36%) is worse than 60.78% of its industry peers.
Industry RankSector Rank
ROA -4.9%
ROE -10.36%
ROIC N/A
ROA(3y)-4.08%
ROA(5y)-2.82%
ROE(3y)-7.87%
ROE(5y)-2.14%
ROIC(3y)N/A
ROIC(5y)N/A
INNV Yearly ROA, ROE, ROICINNV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

INNV has a worse Gross Margin (17.63%) than 64.71% of its industry peers.
In the last couple of years the Gross Margin of INNV has declined.
INNV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 17.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.12%
GM growth 5Y-6.16%
INNV Yearly Profit, Operating, Gross MarginsINNV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 20

More info and screens

3

2. Health

2.1 Basic Checks

INNV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for INNV has been increased compared to 1 year ago.
Compared to 5 years ago, INNV has more shares outstanding
INNV has a better debt/assets ratio than last year.
INNV Yearly Shares OutstandingINNV Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
INNV Yearly Total Debt VS Total AssetsINNV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 2.08 indicates that INNV is not a great score, but indicates only limited risk for bankruptcy at the moment.
INNV has a Altman-Z score of 2.08. This is comparable to the rest of the industry: INNV outperforms 50.00% of its industry peers.
INNV has a Debt/Equity ratio of 0.28. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.28, INNV is doing good in the industry, outperforming 67.65% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Altman-Z 2.08
ROIC/WACCN/A
WACC8.05%
INNV Yearly LT Debt VS Equity VS FCFINNV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

INNV has a Current Ratio of 1.16. This is a normal value and indicates that INNV is financially healthy and should not expect problems in meeting its short term obligations.
INNV has a Current ratio of 1.16. This is in the lower half of the industry: INNV underperforms 67.65% of its industry peers.
INNV has a Quick Ratio of 1.16. This is a normal value and indicates that INNV is financially healthy and should not expect problems in meeting its short term obligations.
INNV has a Quick ratio of 1.16. This is in the lower half of the industry: INNV underperforms 60.78% of its industry peers.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 1.16
INNV Yearly Current Assets VS Current LiabilitesINNV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 47.83% over the past year.
INNV shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.91%.
Measured over the past years, INNV shows a quite strong growth in Revenue. The Revenue has been growing by 10.41% on average per year.
EPS 1Y (TTM)47.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)11.91%
Revenue growth 3Y6.2%
Revenue growth 5Y10.41%
Sales Q2Q%10.64%

3.2 Future

The Earnings Per Share is expected to grow by 51.21% on average over the next years. This is a very strong growth
Based on estimates for the next years, INNV will show a quite strong growth in Revenue. The Revenue will grow by 11.60% on average per year.
EPS Next Y10.15%
EPS Next 2Y57.28%
EPS Next 3Y51.21%
EPS Next 5YN/A
Revenue Next Year12.13%
Revenue Next 2Y11.21%
Revenue Next 3Y11.6%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
INNV Yearly Revenue VS EstimatesINNV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
INNV Yearly EPS VS EstimatesINNV Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

INNV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 43.59, the valuation of INNV can be described as expensive.
The rest of the industry has a similar Price/Forward Earnings ratio as INNV.
The average S&P500 Price/Forward Earnings ratio is at 20.74. INNV is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 43.59
INNV Price Earnings VS Forward Price EarningsINNV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of INNV indicates a slightly more expensive valuation: INNV is more expensive than 65.69% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 229.18
INNV Per share dataINNV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as INNV's earnings are expected to grow with 51.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.28%
EPS Next 3Y51.21%

More info and screens

0

5. Dividend

5.1 Amount

INNV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INNOVAGE HOLDING CORP

NASDAQ:INNV (5/5/2025, 8:18:57 PM)

Premarket: 2.4 -0.49 (-16.96%)

2.89

-0.26 (-8.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-04 2025-02-04/amc
Earnings (Next)05-06 2025-05-06/amc
Inst Owners11.86%
Inst Owner Change0.03%
Ins Owners1.54%
Ins Owner Change0%
Market Cap390.84M
Analysts48
Price Target5.95 (105.88%)
Short Float %1.35%
Short Ratio4.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-148.37%
Min EPS beat(2)-292.16%
Max EPS beat(2)-4.58%
EPS beat(4)1
Avg EPS beat(4)-62.12%
Min EPS beat(4)-292.16%
Max EPS beat(4)62.77%
EPS beat(8)2
Avg EPS beat(8)-55.48%
EPS beat(12)3
Avg EPS beat(12)-88.49%
EPS beat(16)4
Avg EPS beat(16)-71.82%
Revenue beat(2)0
Avg Revenue beat(2)-1.84%
Min Revenue beat(2)-2.58%
Max Revenue beat(2)-1.09%
Revenue beat(4)2
Avg Revenue beat(4)-0.26%
Min Revenue beat(4)-2.58%
Max Revenue beat(4)2.09%
Revenue beat(8)4
Avg Revenue beat(8)-0.49%
Revenue beat(12)5
Avg Revenue beat(12)-0.81%
Revenue beat(16)6
Avg Revenue beat(16)-0.6%
PT rev (1m)0%
PT rev (3m)-2.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.83%
EPS NY rev (1m)0%
EPS NY rev (3m)-82.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.02%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 43.59
P/S 0.48
P/FCF N/A
P/OCF 84.63
P/B 1.57
P/tB 3.75
EV/EBITDA 229.18
EPS(TTM)-0.12
EYN/A
EPS(NY)0.07
Fwd EY2.29%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.03
OCFY1.18%
SpS5.96
BVpS1.84
TBVpS0.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.9%
ROE -10.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 17.63%
FCFM N/A
ROA(3y)-4.08%
ROA(5y)-2.82%
ROE(3y)-7.87%
ROE(5y)-2.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.12%
GM growth 5Y-6.16%
F-Score6
Asset Turnover1.54
Health
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Debt/EBITDA 46.21
Cap/Depr 34.56%
Cap/Sales 0.91%
Interest Coverage N/A
Cash Conversion 310.35%
Profit Quality N/A
Current Ratio 1.16
Quick Ratio 1.16
Altman-Z 2.08
F-Score6
WACC8.05%
ROIC/WACCN/A
Cap/Depr(3y)155.97%
Cap/Depr(5y)146.35%
Cap/Sales(3y)3.3%
Cap/Sales(5y)3.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
EPS Next Y10.15%
EPS Next 2Y57.28%
EPS Next 3Y51.21%
EPS Next 5YN/A
Revenue 1Y (TTM)11.91%
Revenue growth 3Y6.2%
Revenue growth 5Y10.41%
Sales Q2Q%10.64%
Revenue Next Year12.13%
Revenue Next 2Y11.21%
Revenue Next 3Y11.6%
Revenue Next 5YN/A
EBIT growth 1Y37.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year219.92%
EBIT Next 3Y73.37%
EBIT Next 5YN/A
FCF growth 1Y96.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y117.58%
OCF growth 3YN/A
OCF growth 5YN/A